Astrazeneca Ab

Celator Pharmaceuticals, Inc.

Proteostasis Therapeutics, Inc.

Entasis Therapeutics, Inc.

Merrimack Pharmaceuticals, Inc.

Kineta, Inc.

Bolin Geng

Benito Munoz

Dmitri B Kirpotin

Daryl C Drummond

Cecilia M Bastos

Matthew Cullen

Alexander Koshkaryev

Markus Haeberlein

Megan Foley

Suresh K Tipparaju

Ozan Alkan

Bradley Tait

Neil Bifulco

Sheila Irene Hauck

Hoan Huynh

Thomas Francois Durand-Reville

Folkert Reck

Janelle Comita-Prevoir

Brendan Chen

Marshall Morningstar

Hui Xiong

Liang Zhao

Satenig Guler

Shanta Bist

Charles Joseph Eyermann

Ye Wu

Daemian Dussault

Gloria Breault

Helen Mcguire

Helen McGuire

Sheila Hauck

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Proteasome activity enhancing compounds

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

&#x3b2;-lactamase inhibitor compounds

Beta-lactamase inhibitor compounds

The present invention relates to compounds of Formula V(A): that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds of Formula V(A) useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Compounds for the treatment of multi-drug resistant bacterial infections

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Growing community of inventors

Andover, MA, United States of America

Bolin Geng